Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Treatment of patients with perioxisome proliferator-activated receptor-¿ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-¿ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-¿ partial agonist balaglitazone in diabetic patients on stable insulin therapy.
Original language | English |
---|---|
Journal | Diabetes - Metabolism: Research and Reviews (Print Edition) |
Volume | 27 |
Issue number | 4 |
Pages (from-to) | 392-401 |
Number of pages | 10 |
ISSN | 1520-7552 |
DOIs | |
Publication status | Published - 2011 |
ID: 40188970